(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 µM, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystalized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site. (4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19 patients.
(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 µM, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystalized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site. (4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19patients.
Entities:
Keywords:
COVID-19; SARS-CoV-2; antiviral; drug repurposing; virtual screening
Authors: Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier Journal: N Engl J Med Date: 2012-10-17 Impact factor: 91.245
Authors: Daniel Wrapp; Nianshuang Wang; Kizzmekia S Corbett; Jory A Goldsmith; Ching-Lin Hsieh; Olubukola Abiona; Barney S Graham; Jason S McLellan Journal: Science Date: 2020-02-19 Impact factor: 47.728
Authors: Mohamed A A Hussein; Hosni A M Hussein; Ali A Thabet; Karim M Selim; Mervat A Dawood; Ahmed M El-Adly; Ahmed A Wardany; Ali Sobhy; Sameh Magdeldin; Aya Osama; Ali M Anwar; Mohammed Abdel-Wahab; Hussam Askar; Elsayed K Bakhiet; Serageldeen Sultan; Amgad A Ezzat; Usama Abdel Raouf; Magdy M Afifi Journal: Cells Date: 2022-04-21 Impact factor: 7.666
Authors: Shaza M Elhusseiny; Taghrid S El-Mahdy; Nooran S Elleboudy; Ibrahim S Yahia; Mohamed M S Farag; Nasser S M Ismail; Mahmoud A Yassien; Khaled M Aboshanab Journal: Infect Drug Resist Date: 2022-07-02 Impact factor: 4.177
Authors: Mohammed W Al-Rabia; Nabil A Alhakamy; Osama A A Ahmed; Khalid Eljaaly; Ahmed L Aloafi; Ahmed Mostafa; Hani Z Asfour; Ahmed A Aldarmahi; Khaled M Darwish; Tarek S Ibrahim; Usama A Fahmy Journal: Pharmaceutics Date: 2021-02-26 Impact factor: 6.321
Authors: Bruno O Villoutreix; Rajagopal Krishnamoorthy; Ryad Tamouza; Marion Leboyer; Philippe Beaune Journal: Adv Appl Bioinform Chem Date: 2021-04-12
Authors: Nabil A Alhakamy; Osama A A Ahmed; Tarek S Ibrahim; Hibah M Aldawsari; Khalid Eljaaly; Usama A Fahmy; Ahmed L Alaofi; Filippo Caraci; Giuseppe Caruso Journal: Pharmaceuticals (Basel) Date: 2021-02-24
Authors: Raya Soltane; Amani Chrouda; Ahmed Mostafa; Ahmed A Al-Karmalawy; Karim Chouaïb; Abdelwaheb Dhahri; Rami Adel Pashameah; Ahlam Alasiri; Omnia Kutkat; Mahmoud Shehata; Hichem Ben Jannet; Jawhar Gharbi; Mohamed A Ali Journal: Pathogens Date: 2021-05-19
Authors: Ayman Abo Elmaaty; Mohammed I A Hamed; Muhammad I Ismail; Eslam B Elkaeed; Hamada S Abulkhair; Muhammad Khattab; Ahmed A Al-Karmalawy Journal: Molecules Date: 2021-06-21 Impact factor: 4.411
Authors: Ahmed Kandeil; Ahmed Mostafa; Omnia Kutkat; Yassmin Moatasim; Ahmed A Al-Karmalawy; Adel A Rashad; Ahmed E Kayed; Azza E Kayed; Rabeh El-Shesheny; Ghazi Kayali; Mohamed A Ali Journal: Pathogens Date: 2021-06-15